Literature DB >> 16170383

Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway.

Zhuo Zhang1, Hui Wang, Mao Li, Elizabeth R Rayburn, Sudhir Agrawal, Ruiwen Zhang.   

Abstract

Although previous studies suggested that the tumorigenicity of mouse double minute 2 (MDM2) was due to its negative regulation of p53, the p53-independent interactions may be equally as important. During recent studies utilizing MDM2 inhibitors, we noted that E2F transcription factor 1 (E2F1) was down regulated upon inhibition of MDM2, regardless of the p53 status of the cancer. The present study investigated the mechanisms responsible for the MDM2-mediated increase in E2F1 expression. MDM2 prolongs the half-life of the E2F1 protein by inhibiting its ubiquitination. MDM2 displaces SCF(SKP2), the E2F1 E3 ligase. Direct binding between MDM2 and E2F1 is necessary for the negative effects of MDM2 on E2F1 ubiquitination, and deletion of the MDM2 nuclear localization signal does not result in loss of the ability to increase the E2F1 protein level. The downregulation of E2F1 upon MDM2 inhibition was not due to either pRB or p14(Arf). In addition, E2F1 was responsible for at least part of the inhibition of cell proliferation induced by MDM2 knockdown. In conclusion, the present study provides evidence that stabilization of the E2F1 protein is likely another p53-independent component of MDM2-mediated tumorigenesis. More knowledge about the MDM2-E2F1 interaction may be helpful in developing novel anticancer therapies. Oncogene (2005) 24, 7238-7247. doi:10.1038/sj.onc.1208814; published online 19 September 2005.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16170383     DOI: 10.1038/sj.onc.1208814

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  61 in total

1.  The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias.

Authors:  Kensuke Kojima; Jared K Burks; Janine Arts; Michael Andreeff
Journal:  Mol Cancer Ther       Date:  2010-08-24       Impact factor: 6.261

2.  APC/C(Cdc20) targets E2F1 for degradation in prometaphase.

Authors:  Melissa J Peart; Masha V Poyurovsky; Elizabeth M Kass; Marshall Urist; Emmy W Verschuren; Matthew K Summers; Peter K Jackson; Carol Prives
Journal:  Cell Cycle       Date:  2010-10-26       Impact factor: 4.534

3.  Feedback regulation between atypical E2Fs and APC/CCdh1 coordinates cell cycle progression.

Authors:  Michiel Boekhout; Ruixue Yuan; Annelotte P Wondergem; Hendrika A Segeren; Elsbeth A van Liere; Nesibu Awol; Imke Jansen; Rob M F Wolthuis; Alain de Bruin; Bart Westendorp
Journal:  EMBO Rep       Date:  2016-02-05       Impact factor: 8.807

4.  Rbf1 degron dysfunction enhances cellular DNA replication.

Authors:  Nitin Raj; Liang Zhang; Yiliang Wei; David N Arnosti; R William Henry
Journal:  Cell Cycle       Date:  2012-08-16       Impact factor: 4.534

5.  CDKN1C negatively regulates RNA polymerase II C-terminal domain phosphorylation in an E2F1-dependent manner.

Authors:  Yihong Ma; Lu Chen; Gabriela M Wright; Smitha R Pillai; Srikumar P Chellappan; W Douglas Cress
Journal:  J Biol Chem       Date:  2010-01-27       Impact factor: 5.157

6.  CK1alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability.

Authors:  Anne-Sophie Huart; Nicola J MacLaine; David W Meek; Ted R Hupp
Journal:  J Biol Chem       Date:  2009-09-15       Impact factor: 5.157

7.  JAZ mediates G1 cell cycle arrest by interacting with and inhibiting E2F1.

Authors:  Mingli Yang; Song Wu; Jinghua Jia; W Stratford May
Journal:  Cell Cycle       Date:  2011-07-15       Impact factor: 4.534

Review 8.  p53 and E2f: partners in life and death.

Authors:  Shirley Polager; Doron Ginsberg
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

9.  Mdm2 and tumorigenesis: evolving theories and unsolved mysteries.

Authors:  Emir Senturk; James J Manfredi
Journal:  Genes Cancer       Date:  2012-03

10.  Towards inferring time dimensionality in protein-protein interaction networks by integrating structures: the p53 example.

Authors:  Nurcan Tuncbag; Gozde Kar; Attila Gursoy; Ozlem Keskin; Ruth Nussinov
Journal:  Mol Biosyst       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.